Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2010

View Archived Issues

ODE-(S)-HPMPA and ODE-(S)-HPMPC inhibit HIV replication by new mode of action

Interim analysis of SENSE trial data shows superior safety of etravirine vs. efavirenz in HIV

AKN-028 significantly alters gene expression profiles of AML cells

PI3K-alpha inhibitor PIK-75 induces apoptosis of AML cells

Boehringer Ingelheim claims new inhibitors of LFA-1A/ICAM-1 interaction

New inhibitors of insulin-like growth factor 1 receptor presented

Novel antagonists discovered of proteinase-activated PAR1 receptor

Exelixis divulges novel mTORC1 inhibitors

AstraZeneca identifies novel antibacterial agents

Telapristone shows promise in preclinical models of breast cancer

Mitsubishi Tanabe out-licenses bepotastine to Dong-A Pharma for ophthalmic use in Korea

Icagen and Pfizer advance phase I trial of voltage-gated Na(V)1.7 sodium channel inhibitor

FDA requires additional time to review Afrezza NDA

Mesoblast acquires Angioblast Systems

Nordic Pharma collaborates with Nippon Kayaku on Spanidin

ReNeuron advances phase I trial of ReN-001 stem cell therapy

Bill & Melinda Gates Foundation provides grant to TB Alliance

Santarus and Pharming submit BLA to FDA for Rhucin

Sinovac receives SFDA approval to begin trials of EV-71 vaccine

PharmaGap and Queen's University collaborate to develop GAP-107B8 for bladder cancer

Santen files IND application with FDA for Clinical Data's ATL-313 in glaucoma

ExonHit Therapeutics receives grants for AclarusDx and EHT-107 programs

Mitsubishi Tanabe submits application to market FTY-720 in Japan for MS

Shionogi and AnGes to codevelop NFkB decoy oligo

BioSante raises funds to support phase III LibiGel program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...